Karyopharm Therapeutics Inc.
KPTI
$4.64
-$0.06-1.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.02M | 30.54M | 38.78M | 42.79M | 33.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.02M | 30.54M | 38.78M | 42.79M | 33.13M |
| Cost of Revenue | 35.92M | -108.60M | 37.43M | 39.84M | 37.34M |
| Gross Profit | -5.90M | 139.14M | 1.35M | 2.95M | -4.21M |
| SG&A Expenses | 27.35M | 27.19M | 27.63M | 31.07M | 29.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.27M | 61.82M | 65.07M | 70.91M | 66.89M |
| Operating Income | -33.26M | -31.28M | -26.28M | -28.12M | -33.76M |
| Income Before Tax | -23.43M | -30.89M | -32.04M | 23.86M | -37.29M |
| Income Tax Expenses | 36.00K | -109.00K | 28.00K | 67.00K | 71.00K |
| Earnings from Continuing Operations | -23.46M | -30.78M | -32.07M | 23.79M | -37.36M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.46M | -30.78M | -32.07M | 23.79M | -37.36M |
| EBIT | -33.26M | -31.28M | -26.28M | -28.12M | -33.76M |
| EBITDA | -33.18M | -31.20M | -26.20M | -28.03M | -33.67M |
| EPS Basic | -2.77 | -3.67 | -3.85 | 2.26 | -4.85 |
| Normalized Basic EPS | -1.73 | -2.30 | -2.40 | -1.61 | -3.03 |
| EPS Diluted | -2.77 | -3.70 | -3.90 | -2.97 | -4.85 |
| Normalized Diluted EPS | -1.73 | -2.30 | -2.40 | -1.27 | -3.03 |
| Average Basic Shares Outstanding | 8.47M | 8.39M | 8.33M | 8.07M | 7.70M |
| Average Diluted Shares Outstanding | 8.47M | 8.39M | 8.33M | 10.30M | 7.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |